Vesigen Highlights Non-Human Primate Biodistribution of Non-Viral Technology and Functional Delivery of Genome Editors in Vivo at the Cracking the Code, the Dawn of Nucleic Acid Medicines Meeting

CAMBRIDGE - Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, presented data further highlighting the potential of the Company's non-viral ARMM (ARrestin-domain 1 Mediated Microvesicles) technology to deliver novel therapeutic payloads to cell and tissue types relevant to multiple therapeutic areas with high unmet need.

Specifically, the Company presented new data demonstrating retinal biodistribution of engineered ARMMs across multiple species - including non-human primates - and data demonstrating successful in vivo functional delivery of a Cas9/guide RNA gene editing complex. The data were presented at the Cracking the Code: The Dawn of Nucleic Acid Medicines meeting, taking place October 17-19, 2023, in Worcester, MA.

'These data further demonstrate the potential of our non-viral ARMM technology to deliver challenging therapeutic payloads, including gene editing complexes, to multiple cell and tissue types impacted in disease,' said Paulash Mohsen, Chief Executive Officer at Vesigen. 'We have shown that our ARMM technology can successfully deliver functionally active gene editing complexes to Kupffer cells and ameliorate disease in an acute liver injury model. Additional data in mice, minipigs, and non-human primates demonstrated the efficient delivery of subretinally administered ARMMs to the RPE and photoreceptors, cell types associated with multiple retinal diseases. Together, these data sets underscore the transformative capacity of our technology to overcome fundamental delivery challenges that limit the potential of promising new genetic medicines.'

About Vesigen Therapeutics

Vesigen Therapeutics is a biotechnology company developing a novel, non-viral delivery technology for gene editing, RNA, and protein-based therapeutics. Vesigen's patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), can be used to precisely deliver a wide range of payloads to a unique set of tissue and cell types. Vesigen has demonstrated highly efficient in vitro and in vivo functional delivery of a range of payloads across multiple cell types and is committed to developing transformative medicines that address current unmet medical needs. ARMMs were discovered and engineered into a drug delivery system at the Harvard T.H. Chan School of Public Health.

Contact:

Adam Bero

Email: [e-mail]

(C) 2023 Electronic News Publishing, source ENP Newswire